Navigation Links
Smith & Nephew Endoscopy Launches the BICEPTOR(TM) Tenodesis System, the First All-Arthroscopic Procedure for Biceps Tendon Repair

System Can Also Be Used For Mini-Open And Open Surgeries

ANDOVER, Mass., May 20 /PRNewswire-FirstCall/ -- Smith & Nephew's (NYSE: SNN; LSE: SN) Endoscopy Division today announced the launch of the BICEPTOR Tenodesis (TEEN-oh-DEE-sis) System to treat injuries to the biceps tendon in the shoulder.

Smith & Nephew Endoscopy's BICEPTOR Tenodesis System is the first that enables surgeons to re-attach the biceps tendon to the humerus, or upper arm bone, using an all-arthroscopic technique. Other biceps tenodesis techniques require the extra step of withdrawing the damaged end of the biceps tendon from the surgery site and using suture to reinforce it before re-inserting the tendon and re-attaching it.

"The device has really simplified the biceps tenodesis procedure by eliminating steps and shortening the length of the procedure," said Dr. Scott Trenhaile, a shoulder specialist with Rockford Orthopedic Associates and Clinical Assistant Professor of Surgery at University of Illinois College of Medicine at Rockford. "The ability to place the tendon in a bone socket using an all-endoscopic technique without delivering the tendon out of the body is a great feature."

Surgeons typically perform biceps tenodesis procedures in conjunction with rotator cuff repair, and market research shows that tenodesis procedure volume is climbing as surgeons more routinely address this pathology. Surgeons are expected to perform more than 68,000 biceps tenodesis procedures worldwide in 2009 alone.

Using Smith & Nephew Endoscopy's tenodesis system, the surgeon drills a tunnel in the humerus and secures healthy biceps tendon tissue inside it using the BIOSURE(TM) PK Interference Screw. The BIOSURE PK Interference Screw is molded from PEEK(R) by Invibio, a polymer whose strength, stiffness and biocompatibility are similar to those of cortical bone. The screw's tapered shape and thread pattern compress the tendon tissue against the walls of the bone tunnel, providing multiple potential attachment points. With the tendon re-attached, the damaged section of the biceps tendon is cut away.

"Smith & Nephew's innovation over the last several years has given surgeons options as they determine the best tools and techniques for repairing shoulder injuries," said Rebecca White, market manager for shoulder repair at Smith & Nephew Endoscopy. "The BICEPTOR Tenodesis System further expands our treatment portfolio. It enables surgeons to use Smith & Nephew devices from start to finish: positioning the patient, accessing the joint, visualizing and diagnosing the injury, resecting damaged soft tissue and repairing the tears."

    CONTACT::  Molly Manchenton
    Sr. Corporate Communications Specialist
    Smith & Nephew Endoscopy
    (978) 749-1667

(TM)Trademark of Smith & Nephew. Certain Marks Reg. U.S. Pat. & T.M. Off.

About Smith & Nephew

Smith & Nephew is a global medical technology business, specialising in Orthopaedic Reconstruction, Orthopaedic Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

"Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 31 countries around the world. Annual sales in 2008 were $3.8 billion."

This press release contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our operating margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SOURCE Smith & Nephew
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. KGI and Smith College Establish Leadership Forum for Women in Bioscience
6. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
7. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
8. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
9. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
10. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
11. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Post Your Comments:
(Date:11/30/2015)... HOLLISTON, Mass. , Nov. 30, 2015 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered ... has received written notification from The NASDAQ Stock ... minimum bid price requirements. The letter noted that ... of HART,s common stock having exceeded $1.00 per ...
(Date:11/30/2015)... ... 30, 2015 , ... Imagine Exhibitions and Universal Partnerships & ... in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately following the Australia ... tour dates. The Exhibition is based on Universal Pictures’ Jurassic World, one of ...
(Date:11/30/2015)... TapImmune, Inc. (TPIV), a ... peptide and gene-based immunotherapeutics and vaccines for the treatment ... be presenting at the 8 th Annual LD ... PM PT. Dr. John N. Bonfiglio a ... the presentation and will join TapImmune management in meeting ...
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... focuses on a daily routine for managing the life-long ... medication can affect the way the body absorbs it ... their a daily routine are important. The goal of ... patients better manage their hypothyroidism by establishing a daily ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):